Alcanza Clinical Research has announced the acquisition of North Georgia Clinical Research (NGCR), a clinical trials research site located in Woodstock, Georgia.
Founded in 2002, NGCR specializes in general medicine studies involving Alzheimer’s disease prevention, cardiovascular disease, diabetes, digestive conditions, pain, as well as men’s and women’s health indications.
Alcanza Clinical Research is a network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from underrepresented communities. With a network of 22 dedicated research units and several additional sites integrated within specialty clinics, it specializes in a range of conditions across psychiatry, neurology, dermatology and infectious disease therapeutic areas.
According to data captured in the LevinPro HC database, this acquisition represents the 14th clinical trial deal of 2024. There were 42 clinical trial transactions announced during 2023, and 30 announced during 2022.
This also marks Alcanza’s third clinical trials acquisition of 2024. In April 2024, the company announced the addition of Innovation Medical Research Center in Florida and FDI Clinical Research in Puerto Rico. The company has announced five acquisitions since September 2022. Financial terms of the deal were not disclosed.
